Zonisamide versus ACTH for infantile spasms

Angappan, Dhanalakshmi , Jitendra K. Sahu, Prahbhjot Malhi, Pratibha Singhi. Safety, tolerability, and effectiveness of oral zonisamide therapy in comparison with intramuscular adrenocorticotropic hormone therapy in infants with West syndrome. European Journal of Paediatric Neurology. In press.

Highlights

•First study on Zonisamide versus Adrenocorticotropic hormone in a randomized controlled trial manner.

•Oral zonisamide had poor efficacy in infants with West syndrome.

•Oral zonisamide appeared to be safe and tolerable in the study in infants with West syndrome.

Abstract

West syndrome is a distinct, infantile onset, epileptic encephalopathy, associated with poor neurodevelopmental outcome. The present study was designed as a randomized, open-label, pilot study to evaluate the safety, feasibility, and effectiveness of oral zonisamide therapy in comparison with adrenocorticotropic hormone therapy in infants with West syndrome. Thirty infants with West syndrome were randomized to receive treatment with either synthetic, intramuscular adrenocorticotropic hormone (30-60IU) or oral zonisamide (4-25mg/kg/day). The study participants had a long treatment lag and preponderance of male sex (90%). The primary effectiveness outcome measure was the cessation of epileptic spasms at 2 weeks of initiation of therapy and persistent till 6 weeks as per West Delphi consensus statement recommendations. Comparison of efficacies of zonisamide versus adrenocorticotropic hormone was as following: the cessation of epileptic spasms (27% vs. 40%, p=0.70), resolution of hypsarrhythmia at 14 days (20% vs. 33%, p=0.68) and resolution of hypsarrhythmia at 6 weeks (36% vs. 71%, p=0.14). Overall, the study observed a poor efficacy of both adrenocorticotropic hormone and zonisamide therapy, which is probably due to long treatment lag and a high proportion of structural etiology. However, oral zonisamide appeared to be safe and tolerable in the study.

Courtesy of:  https://www.mdlinx.com/journal-summaries/west-syndrome-zonisamide-adrenocorticotropic-hormone/2018/09/25/7545089?spec=neurology